TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17686658

Group type: EXPERIMENTAL
Intervention: Continuous Epidural Infusion (CEI) at 10 mL/h
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: CEI + Patient-Controlled Epidural Analgesia (PCEA) at 5 mL/h with demand dose of 5 mL every 20 minutes
Number of subjects: 195

Group type: COMPARATOR
Intervention: Demand dose-only PCEA (5 mL every 15 minutes)
Number of subjects: 195
Study: 16234430

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational study in Ontario population
Number of subjects: 0
Study: 11889779

Group type: EXPERIMENTAL
Intervention: 1% ketamine 2 ml
Number of subjects: 43

Group type: COMPARATOR
Intervention: Normal saline 2 ml
Number of subjects: 43
Study: 10725769

Group type: EXPERIMENTAL
Intervention: 15 g of inulin with 210 mg of calcium
Number of subjects: 15

Group type: COMPARATOR
Intervention: No inulin with 210 mg of calcium
Number of subjects: 15
Study: 8635177

Group type: EXPERIMENTAL
Intervention: Diethylpropion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 1963648

Group type: EXPERIMENTAL
Intervention: IVGTT (0.33 g/kg glucose solution)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: IVGTT2 (0.5 g/kg glucose solution)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: IVGTT + A (during aminophylline infusion)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: IVGTT3 (after hemodialysis)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal controls (29 healthy volunteers)
Number of subjects: 14
Study: 7005439

Group type: EXPERIMENTAL
Intervention: Suprapubic catheterization
Number of subjects: 109

Group type: COMPARATOR
Intervention: Urethral catheterization
Number of subjects: 109
Study: 31031266

Group type: EXPERIMENTAL
Intervention: e‐learning alone
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: e‐learning combined with simulation‐based training
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 217
Study: 28193490

Group type: EXPERIMENTAL
Intervention: A+PAAC intervention (target ≥100min/week, average delivered 55min/week)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 584
Study: 26618456

Group type: EXPERIMENTAL
Intervention: HYC-24L (Juvéderm Ultra XC, 24 mg/mL hyaluronic acid with 0.3% lidocaine)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (no treatment, delayed treatment)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: HYC-24L
Number of subjects: 213
Study: 24867688

Group type: EXPERIMENTAL
Intervention: Population-based PSA testing
Number of subjects: 420043

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 420043
Study: 22638812

Group type: EXPERIMENTAL
Intervention: Expecting alcohol (n = 37)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Not expecting alcohol (n = 38)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Impulsive individuals expecting alcohol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Non-impulsive individuals
Number of subjects: 75
Study: 19773024

Group type: EXPERIMENTAL
Intervention: Dietetic treatment + cognitive therapy
Number of subjects: 204

Group type: COMPARATOR
Intervention: Dietetic treatment + physical exercise
Number of subjects: 204
Study: 17476558

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 513
Study: 15675270

Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous Intravenous Insulin Infusion (IVII)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multiple Daily Injections (MDI)
Number of subjects: 60
Study: 11807310

Group type: EXPERIMENTAL
Intervention: Increased condom use; prevention campaign for female sex workers
Number of subjects: 0
Study: 9719744

Group type: EXPERIMENTAL
Intervention: Atraucan 26G spinal needle
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sprotte 24G spinal needle
Number of subjects: 106
Study: 1302160

Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg daily
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg daily
Number of subjects: 770

Group type: COMPARATOR
Intervention: Ramipril 10 mg daily
Number of subjects: 770

Group type: COMPARATOR
Intervention: Ramipril 5 mg + Lasix 20 mg daily
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Overall treatment with ramipril
Number of subjects: 770
Study: 3823619

Group type: EXPERIMENTAL
Intervention: Clofibate (500 mg t.i.d.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bezafibrate (200 mg t.i.d.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31542339

Group type: EXPERIMENTAL
Intervention: Intravitreal 2 mg aflibercept every 4 weeks (monthly)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravitreal 2 mg aflibercept every 12 weeks (quarterly)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 29624676

Group type: EXPERIMENTAL
Intervention: Self-reported periodontal screening questions (Yes/No answers)
Number of subjects: 4890
Study: 25891210

Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 14
Study: 24716820

Group type: EXPERIMENTAL
Intervention: Automated insulin bolus advisor (EXP)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control arm (CNL)
Number of subjects: 218
Study: 21827730

Group type: EXPERIMENTAL
Intervention: Telaprevir + PEG‐IFN + RBV for 12 weeks and 24 weeks respectively
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Telaprevir + PEG‐IFN + RBV
Number of subjects: 189
Study: 20236381

Group type: EXPERIMENTAL
Intervention: PITA injections
Number of subjects: 35

Group type: COMPARATOR
Intervention: No PITA injections (Control)
Number of subjects: 35
Study: 17972053

Group type: COMPARATOR
Intervention: GNB3/1429TT and LRP5/1330VV or AV genotypes in males
Number of subjects: 1589

Group type: COMPARATOR
Intervention: GNB3/1429TT and LRP5/1330VV or AV genotypes in females
Number of subjects: 1589

Group type: EXPERIMENTAL
Intervention: GNB3/1429TT and LRP5/1330VV or AV genotypes (combined effect)
Number of subjects: 1589

Group type: EXPERIMENTAL
Intervention: Synergic effects of GNB3/1429TT and LRP5/1330VV or AV
Number of subjects: 1589
Study: 16332728

Group type: EXPERIMENTAL
Intervention: General practitioner with special interest service
Number of subjects: 556

Group type: COMPARATOR
Intervention: Hospital outpatient care
Number of subjects: 556
Study: 12475841

Group type: EXPERIMENTAL
Intervention: 0.5 mL (5 mg) terbutaline + 2 mL of 3% saline solution (group 2)
Number of subjects: 65

Group type: COMPARATOR
Intervention: 0.5 mL (5 mg) terbutaline + 2 mL of 0.9% saline solution (group 1)
Number of subjects: 65
Study: 9804214

Group type: EXPERIMENTAL
Intervention: Chronic low dose r-HFSH (group A)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional r-HFSH (group B)
Number of subjects: 103
Study: 7593449

Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg, twice daily)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 7
Study: 2180831

Group type: EXPERIMENTAL
Intervention: CHO‐5 (5.0 g/100 ml carbohydrate solution)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CHO‐6 (6.0 g/100 ml carbohydrate solution)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CHO‐7.5 (7.5 g/100 ml carbohydrate solution)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water placebo (WP)
Number of subjects: 8
Study: 6990215

Group type: EXPERIMENTAL
Intervention: Labetalol (300 mg twice a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol (80 mg twice a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrallazine (50 mg twice a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrallazine plus Propranolol
Number of subjects: 0
Study: 30668636

Group type: EXPERIMENTAL
Intervention: Treadmill-based reactive balance training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tai Chi training
Number of subjects: 35
Study: 28121710

Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 0
Study: 25660822

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei F19 bid for three days/week for six months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo bid for three days/week for six months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei F19 bid for three days/week for three months and placebo bid for three days/week for the following three months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo bid for three days/week for three months and Lactobacillus paracasei F19 bid for three days/week for the following three months
Number of subjects: 100
Study: 23295853

Group type: EXPERIMENTAL
Intervention: eicosapentaenoic acid + γ‐linolenic acid
Number of subjects: 26

Group type: COMPARATOR
Intervention: standard pediatric enteral formula
Number of subjects: 26
Study: 20850878

Group type: EXPERIMENTAL
Intervention: Regular exercise with moderate‐intensity: 3 metabolic equivalents (3METs), 3 times per week for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no exercise prescription)
Number of subjects: 31
Study: 19584700

Group type: EXPERIMENTAL
Intervention: HIV/HSV-2 coinfected men
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Men with HIV alone
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Men with HSV-2 alone
Number of subjects: 232

Group type: COMPARATOR
Intervention: HIV/HSV-2 uninfected men
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Men with HIV/HSV-2 coinfection
Number of subjects: 232
Study: 17098137

Group type: EXPERIMENTAL
Intervention: Radial epsilon measurement from right endocardial layer (RE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Radial epsilon measurement from left endocardial layer (LE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Radial epsilon measurement from middle layer of septum
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Strain rate (SR) measurement from left endocardial layer (LE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Strain rate (SR) measurement from right endocardial layer (RE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Strain rate (SR) measurement from middle layer of septum
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Longitudinal epsilon measurement for right ventricle
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Left ventricular radial epsilon measurement
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Left ventricular strain rate (SR) measurement
Number of subjects: 30
Study: 14716777

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (vitamin E) 2000 international units per day for 1 year
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 29
Study: 11716166

Group type: EXPERIMENTAL
Intervention: nCPAP treatment (n=33)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 63
Study: 9594761

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 7926290

Group type: EXPERIMENTAL
Intervention: Insulin-resistant group (SI: 0.31 +/‐ 0.06 x 10(‐4) min‐1.pmol/l‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Insulin-sensitive group (SI: 0.92 +/‐ 0.11 x 10(‐4) min‐1.pmol/l‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Insulin-resistant group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Insulin-sensitive group
Number of subjects: 30
Study: 2686428

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 200 mg every 12 hours
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ceftazidime, 2 g every eight hours
Number of subjects: 43
Study: 4933135

Group type: EXPERIMENTAL
Intervention: Deglycyrrhizinated liquorice (Caved-S)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31087047

Group type: EXPERIMENTAL
Intervention: Community treatment orders
Number of subjects: 333
Study: 31327085

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) aid
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group (standard protocols)
Number of subjects: 189
Study: 28842574

Group type: EXPERIMENTAL
Intervention: CellCollector CTC detection in GGNs group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: CellCollector CTC detection in lung cancer group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 66
Study: 25203157

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2,000 IU/day for 12 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 53
Study: 24139766

Group type: EXPERIMENTAL
Intervention: Smoker-to-smoker (S2S) messages
Number of subjects: 39

Group type: COMPARATOR
Intervention: Expert messages
Number of subjects: 39
Study: 21119031

Group type: EXPERIMENTAL
Intervention: HER2-targeted agents (trastuzumab and lapatinib) with standard treatment (taxanes, anthracyclines, capecitabine, anastrozole, letrozole)
Number of subjects: 1848
Study: 19912135

Group type: EXPERIMENTAL
Intervention: Vitrectomy plus 0.05% isotonic ICG‐assisted ILM peeling
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Vitrectomy plus 0.15% trypan blue (TB)‐assisted ILM peeling
Number of subjects: 78

Group type: COMPARATOR
Intervention: Vitrectomy alone without instrumental retinal surface contact (non‐peeling)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Repeated macular hole surgery
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Morphological studies with contrast‐enhanced OCT
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: ILM peeling and intraoperative dyes
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 0.05% intraoperative isotonic ICG with short exposure time
Number of subjects: 78
Study: 17342789

Group type: EXPERIMENTAL
Intervention: HRQL assessment
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: HRQL assessment followed by a structured interview and discussion
Number of subjects: 213

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 213
Study: 15016021

Group type: EXPERIMENTAL
Intervention: AmF/SnF(2) dentifrice and mouthrinse
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sodium fluoride (NaF) dentifrice and mouthrinse
Number of subjects: 80
Study: 11722304

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study: 9417693

Group type: EXPERIMENTAL
Intervention: Gericomplex (ginseng)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 8189774

Group type: EXPERIMENTAL
Intervention: Mail survey
Number of subjects: 100

Group type: COMPARATOR
Intervention: Telephone survey
Number of subjects: 100
Study: 3103245

Group type: EXPERIMENTAL
Intervention: Cefotaxime (3 doses of 1 gram each at induction and 1 and 3 hours later)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cefamandole (3 doses of 1 gram each at induction and 1 and 3 hours later)
Number of subjects: 108
Study: 30431580

Group type: EXPERIMENTAL
Intervention: Cystotome-assisted prechop phacoemulsification surgery (CAPPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional phacoemulsification surgery (CPS)
Number of subjects: 0
Study: 26573010

Group type: EXPERIMENTAL
Intervention: Ajust® (N = 184)
Number of subjects: 368

Group type: COMPARATOR
Intervention: TVT-O™ (N = 184)
Number of subjects: 368
Study: 25558791

Group type: EXPERIMENTAL
Intervention: Frozen-thawed embryo transfer (Group 2)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Blastocyst transfer (Group 1)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Fresh embryo transfer (Group 3)
Number of subjects: 123
Study: 24312178

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (16-24 energy-% from carbohydrates)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low-fat diet (45-56 energy-% from carbohydrates)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet (32-35 energy-% from carbohydrates)
Number of subjects: 21
Study: 22144108

Group type: EXPERIMENTAL
Intervention: Ultrasonographic surveillance every 3 months (Gr3M)
Number of subjects: 1278

Group type: COMPARATOR
Intervention: Ultrasonographic surveillance every 6 months (Gr6M)
Number of subjects: 1278
Study: 20010231

Group type: EXPERIMENTAL
Intervention: Earlier detection and proactive clinical recognition of dyspeptic signs and symptoms
Number of subjects: 0
Study: 17471340

Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment (twice daily for 5 days prior to surgery)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (no mupirocin treatment)
Number of subjects: 37
Study: 12542598

Group type: EXPERIMENTAL
Intervention: Terlipressin 1 mg i.v. at 12‐h intervals (group A)
Number of subjects: 24
Study: 10711411

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (4 IU/m2 per day, subcutaneous injections, every evening for 6 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study: 8808110

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA) for 6 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 25
Study: 1361175

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 330
Study: 6148814

Group type: EXPERIMENTAL
Intervention: Digitalis therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vasodilators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose heparin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical exercises and elastic stockings
Number of subjects: 0
Study: 31170994

Group type: EXPERIMENTAL
Intervention: AITC cough challenge (selective TRPA1 agonist)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Capsaicin cough challenge (selective TRPV1 agonist)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Both AITC and capsaicin challenges
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Demographics of hypersensitivity
Number of subjects: 250
Study: 29106594

Group type: EXPERIMENTAL
Intervention: Estradiol therapy (n = 21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 42
Study: 27041733

Group type: EXPERIMENTAL
Intervention: Pasireotide administration after pancreatic resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25150368

Group type: EXPERIMENTAL
Intervention: Student smoking prevention intervention (visit to an established interactive circuit)
Number of subjects: 3023

Group type: EXPERIMENTAL
Intervention: Student smoking prevention intervention plus a parent intervention
Number of subjects: 3023

Group type: COMPARATOR
Intervention: Control group (visit to an established exercise and nutrition interactive circuit)
Number of subjects: 3023
Study: 22377745

Group type: EXPERIMENTAL
Intervention: Paroxetine 10 mg/d
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/d
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Paroxetine 10 mg/d and 20 mg/d
Number of subjects: 14
Study: 19297314

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 on day 1
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 on day 5 with oblimersen 7 mg/kg/day continuous i.v. infusion on days 1-7
Number of subjects: 111
Study: 17697219

Group type: EXPERIMENTAL
Intervention: Fentanyl 10 microg x ml(‐1) combined with prolonged injection (30 s) (Group IV)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fentanyl 50 microg x ml(‐1) (Group I)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fentanyl 25 microg x ml(‐1) (Group II)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fentanyl 10 microg x ml(‐1) (Group III)
Number of subjects: 200
Study: 15376729

Group type: EXPERIMENTAL
Intervention: Multidimensional gait data analysis technique
Number of subjects: 0
Study: 11374112

Group type: EXPERIMENTAL
Intervention: Astrand protocol
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bruce protocol
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Costill/Fox protocol
Number of subjects: 37
Study: 9710871

Group type: EXPERIMENTAL
Intervention: Carbohydrate solution (0.7 g/kg BW/h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbohydrate solution plus caffeine (5 mg/kg BW)
Number of subjects: 0
Study: 8279597

Group type: EXPERIMENTAL
Intervention: CPR training
Number of subjects: 172
Study: 3056237

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (30 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cefoxitin (30 mg/kg)
Number of subjects: 6
Study: 4881068

Group type: EXPERIMENTAL
Intervention: Suramin 1.0 g, 0.5 g, and 0.25 g dosages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antrypol, Moranyl, and Naganol (brands of suramin)
Number of subjects: 0
Study: 31031098

Group type: EXPERIMENTAL
Intervention: Usual care with causal information (UC + CI)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 94
Study: 28301561

Group type: EXPERIMENTAL
Intervention: 90-minute hatha yoga practice groups twice weekly for 8 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: 90-minute attention control education groups twice weekly for 8 weeks
Number of subjects: 38
Study: 24519034

Group type: EXPERIMENTAL
Intervention: ACE+ group (vitamins A, C, E, and selenium)
Number of subjects: 126

Group type: COMPARATOR
Intervention: ACE- group (standard ISSNHL treatment regimen only)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: ACE+ group
Number of subjects: 126